Genetically engineered biological agents in therapy for systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a prototype for chronic autoimmune disease. Its prevalence is 20 to 70 cases per 100,000 women and varies by race and ethnicity. Despite considerable progress in traditional therapy, many problems associated with the management of these patients need to be immed...
Saved in:
Main Authors: | Elena Aleksandrovna Aseeva, S K Solovyev, E L Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2013-10-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/493 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE EFFICIENCY OF BIOLOGICAL THERAPY AND THE FEATURES OF HUMORAL IMMUNITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: A. A. Mesnyankina, et al.
Published: (2018-07-01) -
Effect of biological agents on B-lymphocyte subpopulations in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2019-03-01) -
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01) -
PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. L. Nasonov, et al.
Published: (2014-06-01) -
THE TIME COURSE OF CHANGES IN B LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING THERAPY WITH BIOLOGICAL AGENTS
by: A. A. Mesnyankina, et al.
Published: (2017-07-01)